atai Beckley bitcoin holdings
A clinical stage psychedelics biotech that paid about $10 million for roughly 100 coins, its first digital asset of any kind.
Key figures
- Bitcoin held
- 58 BTC
- As of
- 2026-08-13
- Rank
- 112 of 165
- Value at current price
- $3.7M
- Share of 21 million
- <0.01%
- Average cost
- $86,207 per BTC
Holdings over time
Cumulative bitcoin held after each disclosed event. The line steps rather than slopes because treasury positions change on purchase dates, not continuously.
We have one dated figure for atai Beckley so far, shown in the table below, and the table says where it came from. A chart needs at least two dated points, and we would rather show nothing than draw a trend through a single figure. This fills in as the company publishes, or as we backfill its earlier announcements.
Every disclosure we have
| Date | Event | Change | Total held | Note | Source |
|---|---|---|---|---|---|
| 2026-08-13 | Tracked | 58 | Tracker sync |
About atai Beckley
atai Beckley develops psychedelic compounds for treatment resistant depression and other mental health conditions, a business with long trial timelines and no product revenue, funded entirely by raised capital.
In 2025 it paid approximately $10.0 million in cash for about 100 bitcoin, and its annual report states that its digital asset holdings consisted exclusively of bitcoin and that it held none at all before that year. There is no ether, no staking and no yield programme attached.
A development stage biotech putting cash into bitcoin is a treasury decision with a specific consequence: the runway that funds clinical trials now moves with the coin price. That is a real risk transfer from shareholders' perspective, and it is worth seeing stated next to the trial pipeline rather than separately from it.
Compared with its neighbours
Sources
Holdings figures and their dates come from the disclosures linked in the history table above. Read the full methodology.